Richard Booton

Richard Booton

Auto-generated profile, based on publicly available information

Richard Booton

Division of Immunology, Immunity to Infection and Respiratory Medicine, The University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2013 in Thorax
Verified
Journal Article
Open access
PDF file
IRI A Du Rand
I A Du Rand
JBJohn F Blaikley
John F Blaikley
RBR Booton
R Booton
NCNazia Chaudhuri
Nazia Chaudhuri
VGV Gupta
V Gupta
OGon behalf of the British Thoracic Society Bronchoscopy Guideline Group
on behalf of the British Thoracic Society Bronchoscopy Guideline Group

8 July 2014 in PLOS Biology
Verified
Journal Article
Open access
PDF file
MJMariam Jamal-Hanjani
Mariam Jamal-Hanjani
AHAlan Hackshaw
Alan Hackshaw
YNYenting Ngai
Yenting Ngai
JSJacqui Shaw
Jacqui Shaw
CDCaroline Dive
Caroline Dive
CSCharles Swanton
Charles Swanton
The importance of intratumour genetic and functional heterogeneity is increasingly recognised as a driver of cancer progression and survival outcome. Understanding how tumour clonal heterogeneity impacts upon therapeutic outcome, however, is still an area of unmet clinical and scientific need. TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy [Rx]), a prospective study of patients with primary non-small cell lung cancer (NSCLC), aims to define the evolutionary trajectories of lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis. By following cancers from diagnosis to relapse, tracking the evolutionary trajectories of tumours in relation to therapeutic interventions, and determining the impact of clonal heterogeneity on clinical outcomes, TRACERx may help to identify novel therapeutic targets for NSCLC and may also serve as a model applicable to other cancer types.

1 January 2012 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
ETEleni Tsitsiou
Eleni Tsitsiou
AWAndrew E. Williams
Andrew E. Williams
SMSterghios A Moschos
Sterghios A Moschos
KPKetan Patel
Ketan Patel
CRChristos Rossios
Christos Rossios
MLMark A. Lindsay
Mark A. Lindsay
Although previous studies have implicated tissue CD4(+) T cells in the development and maintenance of the inflammatory response in asthmatic patients, little is known about the role of CD8(+) T cells. There is now accumulating evidence that microRNAs and other noncoding RNAs are important regulators of T-cell function. We sought to use transcriptomics to determine the activation state of circulating CD4(+) and CD8(+) T cells in patients with nonsevere and severe asthma. mRNA and noncoding RNA expression in circulating T cells was measured by means of microarray, quantitative real-time PCR, or both. Comparison of mRNA expression showed widespread changes in the circulating CD8(+) but not CD4(+) T cells from patients with severe asthma. No changes were observed in the CD4(+) and CD8(+) T cells in patients with nonsevere asthma versus those in healthy control subjects. Bioinformatics analysis showed that the changes in CD8(+) T-cell mRNA expression were associated with multiple pathways involved in T-cell activation. As with mRNAs, we also observed widespread changes in expression of noncoding RNA species, including natural antisense, pseudogenes, intronic long noncoding RNAs (lncRNAs), and intergenic lncRNAs in CD8(+) T cells from patients with severe asthma. Measurement of the microRNA expression profile showed selective downregulation of miR-28-5p in CD8(+) T cells and reduction of miR-146a and miR-146b in both CD4(+) and CD8(+) T cells. Severe asthma is associated with the activation of circulating CD8(+) T cells but not CD4(+) T cells. This response is correlated with the downregulation of miR-146a/b and miR-28-5p, as well as changes in the expression of multiple species of lncRNA that might regulate CD8(+) T-cell function.

1 July 2014 in Chest
Verified
Journal Article
Open access
PDF file
RBRichard Booton
Richard Booton
MLMark A. Lindsay
Mark A. Lindsay
The advent of techniques such as microarrays and high-throughput sequencing has revolutionized our ability to examine messenger RNA (mRNA) expression within the respiratory system. Importantly, these approaches have also uncovered the widespread expression of “noncoding RNAs,” including microRNAs and long noncoding RNAs, which impact biologic responses through the regulation of mRNA transcription and/or translation. To date, most studies of the role of noncoding RNAs have focused on microRNAs, which regulate mRNA translation via the RNA interference pathway. These studies have shown changes in microRNA expression in cells and tissues derived from patients with asthma, pulmonary fibrosis, cystic fibrosis, COPD, and non-small cell lung cancer. Although the evidence is currently limited, we review the work that has been carried out in cell and animal models that has identified the function and mechanism of action of a small number of these microRNAs in disease etiology. In addition to microRNAs, we assess the emerging evidence that long noncoding RNAs regulate respiratory phenotype. Because these investigations into long noncoding RNAs were performed almost exclusively in non-small cell lung cancer, future work will need to extend these into other respiratory diseases and to analyze how microRNAs and long noncoding RNAs interact to regulate mRNA expression. From a clinical perspective, the targeting of noncoding RNAs as a novel therapeutic approach will require a deeper understanding of their function and mechanism of action. However, in the short term, changes in miRNA and long noncoding RNA expression are likely to be of use as biomarkers for disease stratification and/or assessment of drug action.

13 September 2005 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
SSS L Smith
S L Smith
NBN L Bowers
N L Bowers
DBD C Betticher
D C Betticher
OGO Gautschi
O Gautschi
DRD Ratschiller
D Ratschiller
JHJ Heighway
J Heighway
Aurora kinases are key regulators of chromosome segregation during mitosis. We have previously shown by microarray analysis of primary lung carcinomas and matched normal tissue that AURKB (22 out of 37) and AURKA (15 out of 37) transcripts are frequently over-represented in these tumours. We now confirm these observations in a second series of 44 carcinomas and also show that aurora B kinase protein levels are raised in the tumours compared to normal tissue. Elevated levels of expression in tumours are not a consequence of high-level amplification of the AURKB gene. Using a coding sequence polymorphism we show that in most cases (seven out of nine) tumour expression is predominantly driven from one AURKB allele. Given the function of aurora B kinase, we examined whether there was an association between expression levels and genetic instability. We defined two groups of high and low AURKB expression. Using a panel of 10 microsatellite markers, we found that the group showing the higher level of expression had a higher frequency of allelic imbalance (P=0.0012). Analysis of a number of other genes that are strongly and specifically expressed in tumour over normal lung, including SERPINB5, TERT and PRAME, showed marked allelic expression imbalances in the tumour tissue in the context of balanced or only marginally imbalanced relative allelic copy numbers. Our data support a model of early carcinogenesis wherein defects in the process of inactivation of lung stem-cell associated genes during differentiation, contributes to the development of carcinogenesis.

1 October 2010 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
PWPaul Wheatley-Price
Paul Wheatley-Price
FBFiona Blackhall
Fiona Blackhall
SLSiow Ming Lee
Siow Ming Lee
CMC. Ma
C. Ma
LAL. Ashcroft
L. Ashcroft
FSF. A. Shepherd
F. A. Shepherd
Background: Some non-small-cell lung cancer (NSCLC) surgical series have indicated that the positive prognostic effect of female sex is limited to patients with adenocarcinoma. We carried out a retrospective analysis to investigate the role of sex and histology on efficacy, toxicity, and dose delivery after chemotherapy.